Trials / Completed
CompletedNCT03656939
A Safety Study For Prevenar 13 Among Chinese Children
AN OBSERVATIONAL SAFETY STUDY FOR PREVENAR 13 AMONG CHINESE CHILDREN
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21,240 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 1 Month – 24 Months
- Healthy volunteers
- Not accepted
Summary
This is an observational study based on a population-based EHR database.
Detailed description
This observational study based on a population-based EHR database in Yinzhou district of Ningbo city in China is to estimate incidence rates of seizures (including febrile seizures), urticaria and angioedema, apnea, and fever among Chinese children after receiving Prevenar 13. In addition, a validation study including validation of International classification of diseases, tenth revision (ICD-10) codes or ICD-10 code based algorithm for identifying all safety outcomes of interest and a prospective cohort study in a sub-population of the main study will be conducted in order to offset the potential biased results from the main study because of potential misclassification of the safety outcomes of interest due to miscoding and/or undercoding of ICD-10 codes used to identify these safety outcomes in the EHR database.
Conditions
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2020-07-31
- Completion
- 2020-07-31
- First posted
- 2018-09-04
- Last updated
- 2021-08-27
- Results posted
- 2021-08-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03656939. Inclusion in this directory is not an endorsement.